vrt 534

VRT-325 can repair folding defects by promoting dimerization of the two NBDs or by promoting folding of the TMD.VRT-325 accelerates the healing rate of CF cell monolayers.

VRT-534 is a compound that selectively targets connexin 26 (Cx26), demonstrating dose-responsive binding to both wild-type (WT) Cx26 and the mutant Cx26 K188N, with EC50 values of 19 μM and 5 μM, respectively. It has potential applications in research concerning hearing impairment [1].

(R,R)-VRT-534 is the (R,R)-enantiomer of VRT-534. VRT-534 (Compound 3) acts as a chemical chaperone targeting connexin 26 (Cx26). VRT-534 demonstrates dose-dependent binding with recombinant WT Cx26 and mutant Cx26 K188N, with EC50 values of 19 μM and 5 μM, respectively. VRT-534 is applicable in research related to hearing impairments.

(R,R)-VRT-534 is the enantiomer of VRT-534. EBET-1055 is a bromodomain and extra-terminal (BET) PROTAC degrader. It effectively inhibits the growth of pancreatic ductal adenocarcinoma (PDAC). Additionally, EBET-1055 modulates cancer-associated fibroblast (CAF) activity, increasing the activity of all reporter genes in organoid co-cultures.